Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. VTRS
stocks logo

VTRS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
3.50B
-0.75%
0.533
-1.36%
3.31B
+1.76%
0.563
+12.67%
3.63B
+1.28%
0.630
+1.61%
Estimates Revision
The market is revising Upward the revenue expectations for Viatris Inc. (VTRS) for FY2025, with the revenue forecasts being adjusted by 1.3% over the past three months. During the same period, the stock price has changed by 2.48%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.3%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+1.16%
In Past 3 Month
Stock Price
Go Up
up Image
+2.48%
In Past 3 Month
Wall Street analysts forecast VTRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTRS is 11.00 USD with a low forecast of 9.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast VTRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTRS is 11.00 USD with a low forecast of 9.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
3 Hold
1 Sell
Hold
Current: 10.760
sliders
Low
9.00
Averages
11.00
High
14.00
Current: 10.760
sliders
Low
9.00
Averages
11.00
High
14.00
Truist
Buy
initiated
$15
2025-10-15
Reason
Truist
Price Target
$15
2025-10-15
initiated
Buy
Reason
Truist initiated coverage of Viatris with a Buy rating and $15 price target. While acknowledging that legacy Viatris concerns are "still prevalent across the franchise," the firm sees "an affirmative change" in the direction of the company under a refreshed leadership team, supported by a market leading branded portfolio, a progressive generics foothold, and "a robust pipeline with blockbuster potential," the analyst tells investors. Upside could come from an earlier than anticipated return to full operations at the Indore manufacturing facility and pipeline "overdelivery," the analyst added.
Goldman Sachs
Neutral
initiated
$10
2025-06-06
Reason
Goldman Sachs
Price Target
$10
2025-06-06
initiated
Neutral
Reason
Goldman Sachs initiated coverage of Viatris with a Neutral rating and $10 price target. The firm awaits clarity on the company's growth outlook given current structural dynamics in the core business and believes consensus estimates appear fair. On the generics side, it expects modest growth as Goldman monitors Viatris' ability to more meaningfully off-set legacy product erosion via new product launches and portfolio optimization.
Jefferies
Glen Santangelo
Strong Buy
Maintains
$15 → $13
2025-03-07
Reason
Jefferies
Glen Santangelo
Price Target
$15 → $13
2025-03-07
Maintains
Strong Buy
Reason
Piper Sandler
David Amsellem
Hold
Reiterates
$14 → $10
2025-03-05
Reason
Piper Sandler
David Amsellem
Price Target
$14 → $10
2025-03-05
Reiterates
Hold
Reason
Piper Sandler analyst David Amsellem lowered the firm's price target on Viatris to $10 from $14 and keeps a Neutral rating on the shares after hosting a dinner with senior leadership and investors. The firm came away with a better understanding of the company's challenges out of its manufacturing facility in Indore, India. Taking a step back, Piper says that though it would be tempting to assert that shares are now trading at an attractive risk/reward profile at an EV/2025 EBITDA of 6-turns and in the context of what in its view are resolvable manufacturing issues, it would be equally tempting to assert that the lack of visibility into a clear growth catalyst could translate into the shares trading sideways for the foreseeable future.
B of A Securities
Jason Gerberry
Sell
Maintains
$11 → $10
2025-02-28
Reason
B of A Securities
Jason Gerberry
Price Target
$11 → $10
2025-02-28
Maintains
Sell
Reason
Barclays
Balaji Prasad
Sell
Maintains
$12 → $9
2025-02-28
Reason
Barclays
Balaji Prasad
Price Target
$12 → $9
2025-02-28
Maintains
Sell
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Viatris Inc (VTRS.O) is 4.56, compared to its 5-year average forward P/E of 3.91. For a more detailed relative valuation and DCF analysis to assess Viatris Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Overvalued
5Y Average PE
3.91
Current PE
4.56
Overvalued PE
4.50
Undervalued PE
3.32

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
6.16
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
6.60
Undervalued EV/EBITDA
5.72

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.88
Current PS
0.00
Overvalued PS
1.02
Undervalued PS
0.75
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 247.32% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

VTRS News & Events

Events Timeline

(ET)
2025-12-02
12:10:00
Vera Therapeutics Shares Rise 19.2% to $39.35
select
2025-11-11 (ET)
2025-11-11
09:55:01
Significant Early Gainers in Liquid Options on November 11th
select
2025-11-06 (ET)
2025-11-06
07:23:55
Viatris increases FY25 adjusted EPS forecast to $2.25-$2.35, up from $2.16-$2.30
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
12-03NASDAQ.COM
PinnedVentas Subsidiary Sets Public Offering Price for $500 Million in 5.000% Senior Notes Maturing in 2036

  • Public Offering Announcement: Ventas, Inc. has announced a public offering of $500 million in 5.000% Senior Notes due 2036, priced at 99.510% of the principal amount.

  • Use of Proceeds: The proceeds from the offering will be used for general corporate purposes, including potential repayment of other debts and covering related fees and expenses.

  • Maturity Date: The Senior Notes will mature on February 15, 2036, and are guaranteed by Ventas Realty, Limited Partnership.

  • Joint Book-Running Managers: The offering is being managed by Wells Fargo Securities, LLC, BBVA Securities Inc., J.P. Morgan Securities LLC, Mizuho Securities USA LLC, and RBC Capital Markets, LLC.

[object Object]
Preview
8.0
12-04SeekingAlpha
Mark Cuban advocates for eliminating fees on generic drug applications to enhance domestic production.

  • Mark Cuban's Proposal: Mark Cuban is advocating for the Trump administration to eliminate the $360K regulatory fee for generic drug applications to boost domestic production of high-cost generic medications.

  • Cost Plus Drugs' Capability: Cuban stated that if the fees are waived, Cost Plus Drugs could begin manufacturing expensive generic drugs, such as those for rare diseases, within a year from their Dallas facility.

[object Object]
Preview
7.5
12-01Globenewswire
Mapi Pharma to Seek Partnerships at Evercore Healthcare Conference
  • Partnership Exploration: Mapi Pharma will participate in the 8th Annual Evercore Healthcare Conference from December 2-4, 2025, actively seeking partnerships for its innovative long-acting injectable products to accelerate development and expand market reach.
  • Pipeline Update: The company's GA Depot product is under a commercialization agreement for Relapsing Forms of Multiple Sclerosis, while diabetes and schizophrenia products are in Phase II trials, indicating significant market potential.
  • Technological Edge: Mapi Pharma leverages its proprietary long-acting Depot technology to develop Lifecycle Management products, backed by strong intellectual property, enabling efficient market entry and enhancing competitive positioning.
  • Leadership Insights: CEO Ehud Marom highlighted several promising partnership opportunities in Huntington's disease and breast cancer, emphasizing the company's capability to co-develop long-acting injectable drugs with other firms, thereby increasing market attractiveness.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Viatris Inc (VTRS) stock price today?

The current price of VTRS is 10.76 USD — it has decreased -0.74 % in the last trading day.

arrow icon

What is Viatris Inc (VTRS)'s business?

Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.

arrow icon

What is the price predicton of VTRS Stock?

Wall Street analysts forecast VTRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTRS is 11.00 USD with a low forecast of 9.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Viatris Inc (VTRS)'s revenue for the last quarter?

Viatris Inc revenue for the last quarter amounts to 3.76B USD, increased 0.23 % YoY.

arrow icon

What is Viatris Inc (VTRS)'s earnings per share (EPS) for the last quarter?

Viatris Inc. EPS for the last quarter amounts to -0.11 USD, decreased -237.50 % YoY.

arrow icon

What changes have occurred in the market's expectations for Viatris Inc (VTRS)'s fundamentals?

The market is revising Upward the revenue expectations for Viatris Inc. (VTRS) for FY2025, with the revenue forecasts being adjusted by 1.3% over the past three months. During the same period, the stock price has changed by 2.48%.
arrow icon

How many employees does Viatris Inc (VTRS). have?

Viatris Inc (VTRS) has 32000 emplpoyees as of December 05 2025.

arrow icon

What is Viatris Inc (VTRS) market cap?

Today VTRS has the market capitalization of 12.39B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free